Maravai LifeSciences (MRVI) to Release Earnings on Thursday

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) will issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.00 per share for the quarter. Maravai LifeSciences has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company's earnings conference call can do so using this link.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.08) EPS for the quarter. Maravai LifeSciences had a negative return on equity of 4.78% and a negative net margin of 47.41%. The business had revenue of $73.40 million for the quarter, compared to the consensus estimate of $71.64 million. During the same quarter in the previous year, the firm earned ($0.06) earnings per share. The company's revenue for the quarter was up 6.5% on a year-over-year basis. On average, analysts expect Maravai LifeSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Maravai LifeSciences Stock Performance

NASDAQ MRVI traded down $0.22 during trading hours on Thursday, reaching $7.41. 1,375,118 shares of the company were exchanged, compared to its average volume of 2,218,729. The company has a quick ratio of 9.28, a current ratio of 10.00 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $1.87 billion and a P/E ratio of -7.48. Maravai LifeSciences has a 1 year low of $4.52 and a 1 year high of $11.56. The business's 50 day simple moving average is $8.30 and its 200-day simple moving average is $8.51.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MRVI. UBS Group upped their price objective on Maravai LifeSciences from $8.50 to $11.00 and gave the company a "neutral" rating in a research note on Thursday, August 8th. Morgan Stanley downgraded Maravai LifeSciences from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $11.00 to $10.00 in a research note on Tuesday, August 13th. Royal Bank of Canada restated an "outperform" rating and issued a $15.00 price objective on shares of Maravai LifeSciences in a research note on Friday, August 16th. The Goldman Sachs Group reduced their target price on shares of Maravai LifeSciences from $8.00 to $7.00 and set a "neutral" rating for the company in a research note on Tuesday, October 8th. Finally, Wells Fargo & Company initiated coverage on shares of Maravai LifeSciences in a research note on Tuesday, August 27th. They set an "overweight" rating and a $10.00 price target on the stock. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $10.67.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.